Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors

Felicia Stefania Falvella; Elena Ricci; Stefania Cheli; Chiara Resnati; Valeria Cozzi; Dario Cattaneo; Cristina Gervasoni; Emilio Clementi; Massimo Galli; Agostino Riva

doi:10.1515/dmpt-2017-0006

Home Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors

Article

Licensed

Unlicensed Requires Authentication

Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors

Felicia Stefania Falvella , Elena Ricci , Stefania Cheli , Chiara Resnati , Valeria Cozzi , Dario Cattaneo , Cristina Gervasoni , Emilio Clementi , Massimo Galli and Agostino Riva

Published/Copyright: April 12, 2017

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 32 Issue 2

MLA
APA
Harvard
Chicago
Vancouver

MLA
APA
Harvard
Chicago
Vancouver

Falvella, Felicia Stefania, Ricci, Elena, Cheli, Stefania, Resnati, Chiara, Cozzi, Valeria, Cattaneo, Dario, Gervasoni, Cristina, Clementi, Emilio, Galli, Massimo and Riva, Agostino. "Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors" Drug Metabolism and Personalized Therapy, vol. 32, no. 2, 2017, pp. 115-117. https://doi.org/10.1515/dmpt-2017-0006

Falvella, F., Ricci, E., Cheli, S., Resnati, C., Cozzi, V., Cattaneo, D., Gervasoni, C., Clementi, E., Galli, M. & Riva, A. (2017). Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metabolism and Personalized Therapy, 32(2), 115-117. https://doi.org/10.1515/dmpt-2017-0006

Falvella, F., Ricci, E., Cheli, S., Resnati, C., Cozzi, V., Cattaneo, D., Gervasoni, C., Clementi, E., Galli, M. and Riva, A. (2017) Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metabolism and Personalized Therapy, Vol. 32 (Issue 2), pp. 115-117. https://doi.org/10.1515/dmpt-2017-0006

Falvella, Felicia Stefania, Ricci, Elena, Cheli, Stefania, Resnati, Chiara, Cozzi, Valeria, Cattaneo, Dario, Gervasoni, Cristina, Clementi, Emilio, Galli, Massimo and Riva, Agostino. "Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors" Drug Metabolism and Personalized Therapy 32, no. 2 (2017): 115-117. https://doi.org/10.1515/dmpt-2017-0006

Falvella F, Ricci E, Cheli S, Resnati C, Cozzi V, Cattaneo D, Gervasoni C, Clementi E, Galli M, Riva A. Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metabolism and Personalized Therapy. 2017;32(2): 115-117. https://doi.org/10.1515/dmpt-2017-0006

Copy

Copied to clipboard

BibTeX EndNote RIS

Received: 2017-2-11

Accepted: 2017-3-1

Published Online: 2017-4-12

Published in Print: 2017-5-24

You are currently not able to access this content.

Articles in the same Issue

Frontmatter
Review
An update on HLA alleles associated with adverse drug reactions
Original Articles
Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients
Novel therapeutic approaches of natural oil from black seeds and its underlying mechanisms against kidney dysfunctions in haloperidol-induced male rats
Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients
Letter to the Editor
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors
Congress Report
8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3–5 October 2016

Search journal Search the content of this journal

https://doi.org/10.1515/dmpt-2017-0006

Keywords for this article

atazanavir; CYP3A; hyperbilirubinemia; PPARA; UGT1A1

Articles in the same Issue

Frontmatter
Review
An update on HLA alleles associated with adverse drug reactions
Original Articles
Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients
Novel therapeutic approaches of natural oil from black seeds and its underlying mechanisms against kidney dysfunctions in haloperidol-induced male rats
Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients
Letter to the Editor
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors
Congress Report
8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3–5 October 2016